COVID-19, SARS-CoV-2 Clinical Trial
A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19
The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.
The purpose of this study is to demonstrate the safety and characterize the immunogenicity of AZD1222; AstraZeneca's candidate ChAdOx1 vector vaccine against SARS-CoV-2 (nCoV-19) in previously unvaccinated immunocompromised adults. ;